Mark Rolfe
Impact in
- Molecular Biology top 1%
- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- Cell death mechanisms and regulation
- Oncology top 2%
- Cancer-related Molecular Pathways
Papers in
-
- Ubiquitin and proteasome pathways 26
- Protein Degradation and Inhibitors 12
-
- NF-κB Signaling Pathways 3
- Cancer Genomics and Diagnostics 2
- Co-authors
- Peggy Beer‐Romero (5 shared papers)Michele Pagano (4 shared papers)Anne M. Theodoras (4 shared papers)Giulio Francesco Draetta (3 shared papers)Sun W. Tam (2 shared papers)Giannino Del Sal (1 shared paper)P. Renée Yew (1 shared paper)Vincent Chau (1 shared paper)
- Journals
- Blood (7 papers)Molecular Cancer Therapeutics (5 papers)Clinical Cancer Research (4 papers)Oncogene (2 papers)Journal of Medicinal Chemistry (2 papers)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Mark Rolfe
49 papers receiving 8.3k citations
Mark Rolfe's Hit Papers
Peers
Comparison fields: 5 of 115
- Molecular Biology 5.1k
- Oncology 1.2k
- Cell Biology 699
- Hematology 491
- Cancer Research 390
Countries citing papers authored by Mark Rolfe
This map shows the geographic impact of Mark Rolfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Rolfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Rolfe more than expected).
Fields of papers citing papers by Mark Rolfe
This network shows the impact of papers produced by Mark Rolfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Rolfe. The network helps show where Mark Rolfe may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Rolfe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer Hit paper breakdown → | 2009 | 1705 |
| 2 | Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27 Hit paper breakdown → | 1995 | 1635 |
| 3 | A 20s complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B Hit paper breakdown → | 1995 | 804 |
| 4 | 2006 | 533 | |
| 5 | 2010 | 439 | |
| 6 | 2010 | 405 | |
| 7 | 2015 | 330 | |
| 8 | 2010 | 294 | |
| 9 | 2018 | 268 | |
| 10 | 2004 | 244 | |
| 11 | 2009 | 195 | |
| 12 | 2020 | 170 | |
| 13 | 2006 | 148 | |
| 14 | 1997 | 98 | |
| 15 | 2017 | 96 | |
| 16 | 1997 | 93 | |
| 17 | 2006 | 93 | |
| 18 | 2002 | 91 | |
| 19 | 1995 | 86 | |
| 20 | 2020 | 78 |
About Mark Rolfe
Mark Rolfe is a scholar working on Molecular Biology, Cancer Research, Hematology, Oncology and Pathology and Forensic Medicine, having authored 54 papers that have together received 8.6k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (26 papers), Protein Degradation and Inhibitors (12 papers), NF-κB Signaling Pathways (3 papers), Prostate Cancer Treatment and Research (3 papers), Multiple Myeloma Research and Treatments (3 papers), Lymphoma Diagnosis and Treatment (3 papers), Cancer-related Molecular Pathways (2 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Molecular Biology (5.1k citations), Oncology (1.2k citations), Cell Biology (699 citations), Hematology (491 citations) and Cancer Research (390 citations). Mark Rolfe has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Peggy Beer‐Romero, Michele Pagano, Anne M. Theodoras, Giulio Francesco Draetta, Sun W. Tam, Giannino Del Sal, P. Renée Yew, Vincent Chau, Jeffrey Wade Harper and Grzegorz Nalepa. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, Clinical Cancer Research, Oncogene and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.